NANoREG D5 07 SOP 10

NANoREG D5.03 DR In vitro screening methodology for absorption or crossing of other barriers

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d503-dr-in-vitro-screening-methodology-for-absorption-or-crossing-of-other 

SOPs available in deliverable:

• SOP 01 Protocol for organotypic cell culture modified for exposure to nanomaterials
• SOP 02 Caco-2 cell culture and differentiation
• SOP 03 Evaluation of NMs impact on Caco-2 cell barrier model

NANoREG D3 05 DR Development of an aquatic Mesocosms Platform

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d3-05-dr-development-of-aquatic-mesocosms-platform 

NANoREG D5.07 SOP 13 HEL16T009 Mouse Lymphoma Assay in vitro

Acesse:

https://www.rivm.nl/documenten/nanoreg-d507-sop-13-hel16t009-mouse-lymphoma-assay-in-vitro 

NANoREG D1.07 DR Case studies of the different investigated materials

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d107-dr-case-studies-of-different-investigated-materials

NANoREG D1.02 DR Regulatory data gaps and research needs

Acesse:

https://www.rivm.nl/en/documenten/nanoreg-d102-dr-regulatory-data-gaps-and-research-needs

NANoREG D5.07 SOP 09 TaqMan real-time Reverse Transcription PCR

Acesse:

https://www.rivm.nl/documenten/nanoreg-d507-sop-09-taqman-real-time-reverse-transcription-pcr